Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decline in Short Interest

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 19,000 shares, a decline of 92.1% from the December 31st total of 241,700 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average daily volume of 325,400 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Aptevo Therapeutics in a research report on Monday, December 9th. They set a “sell” rating for the company.

Aptevo Therapeutics Stock Up 0.9 %

Aptevo Therapeutics stock opened at $4.53 on Wednesday. The stock’s 50 day moving average is $85.17 and its 200 day moving average is $297.46. Aptevo Therapeutics has a one year low of $3.65 and a one year high of $399.60.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.